Effective and safe control of glycemia with insulin Apidra - the recipe for success of type 2 diabetes prophylaxis
https://doi.org/10.14341/2072-0351-5816
Abstract
Current possibilities for the use of ultra-short acting insulin analogs are discussed. The importance of control of postprandial hyperglycemia is emphasized.Pharmacological properties of insulin glulisine are described with special reference to its advantage over human ultra-short acting insulin.An important characteristic of glulisine is the possibility of its efficacious use for the treatment of obese patients. The results of GINGER and CHOinternational studies suggest high efficacy and safety of glulisine used for intensive insulin therapy according to both flexible and fixed regimens.
References
1. International Diabetes Federation http://www.idf.org
2. Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. // Сахар- ный диабет. - 2007. - 3. - С. 55-57.
3. Koro C.E., Bowlin S.J., Bourgeois N., Fedder D.O. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report // Diabetes Care. - 2004. - № 27. - С.17-20.
4. Duckworth W., Abraira C, Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. // N. Engl. J. Med. - 2009. - № 360. - Р. 129-139.
5. Ruigomez A., Rodrigues L.A. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor // Eur. J. Epidemiol. - 1998. - № 14(15). - Р. 439-445.
6. Testa M.A., Simonson D.S. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized controlled, double-blind trial // JAMA. - 1998. - № 280. - Р. 1490-1496.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - № 352. - Р. 837-853.
8. DeWitt D.E., Hirch I.B. Outpatient insulin therapy in type 1 and 2 diabetes mellitus. // JAMA. - 2003. - № 289(17). - Р. 2254-2264.
9. White J.R. Jr., Campbell R.K., Hirsch I. Insulin analogues: new agents for improving glycemic control // Postgrad Med. - 1997. - № 101(2). - Р. 58-70.
10. Robertson C. Physiologic insulin replacement in type 2 diabetes // The Diabetes Educator. - 2006. - № 3. - Р. 423-432.
11. Garg S.K., Ellis S.L., Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes // Expert Opinion on Pharmacotherapy. - 2005. - № 4. - Р. 643-651.
12. Raccah D., Bretzel R.G., Owens D., Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? // Diabetes Metab. Res. Rev. - 2007. - № 23. - Р. 257-264.
13. Shim W.S., Kim S.K., Kim H.J. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes // Eur. J. Endocrinol. - 2006. - № 155(4). - Р. 615-622.
14. O'Rahilly S., John Savill J. Science, medicine, and the future non-insulin dependent diabetes mellitus: the gathering storm // BMJ. - 1997. - № 314 (29). - Р. 955-967.
15. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? // Diabetes. - 2005. - № 54. - Р. 1-7.
16. Home P.D. Postprandial hyperglycaemia: mechanisms and importance // Diabetes Obesity Metab. - 2000. - № 2 (Suppl 1). - S7-S11.
17. Node K., Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure // Cardiovascular Diabetology. - 2009. - № 8. - http://www.cardiab.com/content/8/1/23.
18. Berger M., Cuppers H.J., Hegner H. et al. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations // Diabetes Care. - 1982. - № 5. - Р. 77-91.
19. Overmann H., Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it // Diabetes Res. Clin. Pract. - 1999. - № 43(2). - Р. 137-142.
20. Singh S. R., Ahmad F., Lal A. et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis // CMAJ. - 2009. - № 180(4). - Р. 385-397.
21. Дедов И.И., Шестакова М.В., Моисеев С.В Аналоги инсу- лина // Клин. фармакология и терапия. - 2005. - № 2. - С. 49-55.
22. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. Апидра - новый аналог инсулина для лечения сосудистых осложнений при сахарном диабет // Проблемы эндокринологии. - 2007. - № 3. - С. 35-38.
23. Анциферов М.Б., Моргунов Л.Ю. Применение базально-болюс- ного режима инсулинотерапии у больных с сахарным диабетом 2 типа // Фарматека. - 2009. - № 20. - С. 50-55.
24. Becker R.H., Frick A.D., Burget F. et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin glulisine, regular human insulin in healthy volunteers using the euglycemic clamp technique // Exp. Clin. Endocrinol. Diabetes. - 2005. - № 113. - Р. 292-297.
25. Becker R.H., Frick A.D. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine // Clin. Pharmacokinet. - 2008. - № 47. - Р. 7-20.
26. Becker R.H.A. Frick A.D., Burger F. et al. Insulin glulisine, a new rapidacting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects // Exp. Clin. Endocrinol. Diabetes. - 2005. - № 113. - Р. 435-443.
27. Heise T., Nosek L., Spitzer H. et al. Insulin glulisine: a faster onset of action compared with insulin lispro // Diabetes Obes. Metab. - 2007. - № 9. - Р. 746-753.
28. Arnolds S. S., Rave K., Hövelmann U. Insulin Glulisine has a faster onset of action compared with insulin aspart in healthy voluntees // Exp. Clin. Endocrinol. Diabetes. - 2010. - № 118. - Р. 662-664.
29. Bernett A.H. How well do rapid-acting insulin work in obese individuals // Diabetes Obes. Metab. - 2006. - № 8. - Р. 388-395
30. Hirsch Irl. B., Bergenstal R.M., Parkin C.G. et al. A real-world approach to insulin therapy in primary care practice // Clinical Diabetes. - 2005. - № 2 (23). - Р. 78-86.
31. Fritsche A., Larbig M., Owens D.Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study // Diabetes, Obesity and Metabolism. - 2010. - № 12. - Р. 115-123.
32. Bergenstal R.M., Johnson M., Powers M.A. et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine // Diabetes Care. - 2008. - № 31(7). - 1305-1310.
Review
For citations:
Biryukova E.V. Effective and safe control of glycemia with insulin Apidra - the recipe for success of type 2 diabetes prophylaxis. Diabetes mellitus. 2011;14(4):46-50. (In Russ.) https://doi.org/10.14341/2072-0351-5816
Views:
1201
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
